SCHEMBL712689

SCHEMBL712689

C1=CC(N2CCNCC2)=CCC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 8/20 0.38
HTR3E A5X5Y0 2/20 0.38
HTR3B O95264 2/20 0.38
HTR3A P46098 2/20 0.38
HTR3D Q70Z44 2/20 0.38
HTR3C Q8WXA8 2/20 0.38
SIGMAR1 Q99720 2/20 0.38
ALDH1A1 P00352 3/20 0.35
ADRB2 P07550 2/20 0.35
PLD1 Q13393 2/20 0.35
KDM4E B2RXH2 1/20 0.35
CHRM2 P08172 1/20 0.35
CHRM4 P08173 1/20 0.35
CHRM1 P11229 1/20 0.35
CHRM3 P20309 1/20 0.35
NCF1 P14598 1/20 0.35
LMNA P02545 1/20 0.33
HRH1 P35367 1/20 0.33
USP2 O75604 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18945764 0.88 ADRB1 (0.37) ADRB1HTR3EHTR3BHTR3AHTR3D
SCHEMBL19393633 0.82 ADRB1 (0.37) ADRB1HTR3EHTR3BHTR3AHTR3D
SCHEMBL14627790 0.80
Bromide SCHEMBL7295860 0.78
SCHEMBL16501134 0.75 LMNA (0.38) ALDH1A1KDM4ELMNAUSP2HSD17B10
SCHEMBL18756387 0.75 ADRA2C (0.35) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL18932506 0.75
SCHEMBL19186925 0.71 CYP2D6 (0.33) ADRB1HTR3EHTR3BHTR3AHTR3D
SCHEMBL22540727 0.71 KDM4E (0.41) KDM4EUSP2
SCHEMBL29745063 0.70 ADRB1 (0.33) ADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115551850-A Small molecule inhibitors of galectin-3 百时美施贵宝公司 2022-12-30 CN disclosed
CN-114787136-A Substituted benzimidazole carboxamides and their use in the treatment of medical disorders 比亚尔R&D投资股份公司 2022-07-22 CN disclosed
CN-104031054-A Chemokine receptor antagonists and methods of use thereof MILLENNIUM PHARM INC 2014-09-10 CN disclosed
CN-1585772-B chemokine receptor antagonists and methods and uses thereof MILLENNIUM PHARM INC 2014-06-04 CN disclosed
WO-2013045400-A1 PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-04-04 WO disclosed
US-8124720-B2 Triazine-based monomeric compound, di-triazine compound, and degradable polymer NATIONAL CHI NAN UNIVERSITY (TW) 2012-02-28 US disclosed
US-20090312520-A1 Triazine-Based Monomeric Compound, Di-Triazine Compound, and Degradable Polymer NATIONAL CHI NAN UNIVERSITY (TW) 2009-12-17 US disclosed
WO-2009091324-A1 QUINOLINE, NAPHTHALENE AND CONFORMATIONALLY CONSTRAINED QUINOLINE OR NAPHTHALENE DERIVATES AS ANTI-MYCOBACTERIAL AGENTS CHATTOPADHYAYA JYOTI (SE) 2009-07-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312520-A1 Triazine-Based Monomeric Compound, Di-Triazine Compound, and Degradable Polymer CCNB2, CCND2, CCNB1 ADRB1 1093/4885HTR3E 2170/4885HTR3B 1365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.